Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase I drugs for Anaplastic Large Cell Lymphoma (ALCL) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Itezocabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Itezocabtagene autoleucel overview
Itezocabtagene autoleucel (TT-11) is under investigation for the treatment of relapsed/refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma, anaplastic large cell lymphoma, peripheral T cell lymphoma, extranodal natural killer cell lymphomas /T-cell lymphoma, diffuse large B cell lymphoma and primary mediastinal large B-cell lymphoma (PMBCL). The therapeutic candidate is administered as intravenous injection. It comprises of CTLs genetically modified with EBVs to express chimeric antigen receptors targeting CD30L receptors.
Tessa Therapeutics overview
Tessa Therapeutics is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products for cancers including gastric carcinoma, cervical, nasopharyngeal, head, oropharyngeal, and neck cancer. It harnesses virus-specific T cell (VST) technology for the treatment of solid tumors. Tessa Therapeutics is also extending its VST platform and treat an array of solid tumors through combinatorial approaches with chimeric antigen receptors, antibodies, and oncolytic virus technologies. The company works in partnership with National Cancer Centre, Singapore, Baylor College of Medicine, and Agency for Science, Technology and Research. Tessa Therapeutics is headquartered in Singapore.
For a complete picture of Itezocabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.